Xiamen LP Pharmaceutical Co., Ltd.

Avinash Singh

Rongbin Ling

Haijian Zhu

Fuxiang Lin

Xiaojin Xiao

Liyan Xie

Zhoue Gao

Ying Ye

Liyuan Chen

The present invention provides an oral patch for localized treatment of mouth ulcers containing combination of tetracaine and triamcinolone as active drugs. The patch is a bilayer structure containing a drug layer with amorphous tetracaine hydrochloride and amorphous triamcinolone acetonide and a water-soluble backing layer without a drug. The oral patch with combination of drugs has improved efficacy over each individual drug. The drug layer comprises 3-20% by weight of amorphous tetracaine hydrochloride, or a pharmaceutical acceptable salt thereof, 0.1-2.0% by weight of amorphous triamcinolone acetonide or a pharmaceutical acceptable salt thereof, 20-95% by weight of a first film-forming material, 1-12% by weight of an adhesive, 1-20% by weight of one or more cooling agent, and optionally 1-12% by weight of a plasticizer. The backing layer comprises 70-95% by weight of one or more film-forming agents, 2-10% by weight of a plasticizer and optionally 1-8% by weight of a flavoring agent.

Oral patch for treating mouth ulcers

The present invention provides an oral transmucosal film for delivering agomelatine through the buccal mucosa or sublingual mucosa. The film is a bilayer structure containing a mucoadhesive layer with amorphous agomelatine and a water-soluble backing layer without agomelatine. The film has improved bioavailability and improved palatability. The mucoadhesive layer comprises comprising 0.1%-40% by weight of amorphous agomelatine, or a pharmaceutical acceptable salt thereof, 50-98% by weight of a first film-forming material, 0.5-20% by weight of an oil phase excipient, and 0.5-17% by weight of a surfactant. The backing layer comprises 60-100% (w/w) of one or more film-forming agents.

Agomelatine oral transmucosal film

The present invention provides an oral transmucosal film for delivering tadalafil through the buccal mucosa or sublingual mucosa. The film is a single layer structure containing amorphous tadalafil, one or more solubilizers, one or more penetration enhancers, and one or more adhesives to deliver the drug through a transmucosal route. Comparing with an oral tadalafil tablet, the present oral transmucosal film provides improved absorption rate and Tmax. The oral transmucosal film comprises 5%-60% by weight of amorphous tadalafil, 25-96% by weight of a film-forming material, 1-20% by weight of a solubilizer, 0.5-10% by weight of a penetration enhancer, and 1-15% by weight of an adhesive.

Tadalafil oral transmucosal film

Growing community of inventors

Xiamen, China

Avinash Singh